Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Fredun Pharmaceuticals approved its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with a clean (unmodified) limited review report from statutory auditor R.H. Nisar & Co. Standalone net sales for Q3 FY26 jumped to Rs. 15,992.63 lakhs, up about 57% from Rs. 10,184.09 lakhs in Q3 FY25, while net profit nearly doubled to Rs. 1,047.81 lakhs (vs Rs. 533.26 lakhs). For the nine months, revenue rose to Rs. 42,291.45 lakhs and PAT to Rs. 2,697.62 lakhs, up roughly 48% and 96% respectively year-on-year. Basic EPS for Q3 stood at Rs. 22.19 versus Rs. 11.29 a year earlier, reflecting strong operating leverage. Finance costs, however, remained elevated at Rs. 1,054.95 lakhs in the quarter, indicating a higher debt or interest burden.
Strong topline and bottomline growth, along with margin expansion, is a positive signal for shareholders and may support a positive short-term stock reaction; investors should, however, watch the rising finance costs and debt level, which could weigh on sustainability of the growth if not moderated.